Welcome to our dedicated page for Icl Group news (Ticker: ICL), a resource for investors and traders seeking the latest updates and insights on Icl Group stock.
ICL Group Ltd. reports financial and operating developments as a global specialty minerals company serving agriculture, food and industrial markets. The company’s updates center on its phosphate solutions, potash, industrial products and growing solutions activities, including fertilizer products, specialty food solutions, bromine-based resources and mineral-based engineered materials.
Recurring announcements include quarterly and annual results, earnings calls, dividend actions, production capacity additions and strategic portfolio initiatives. Recent operating themes include Water Soluble Fertilizer manufacturing in India, the use of potash, phosphate and bromine resources across end markets, and corporate governance updates tied to executive management and board decisions.
ICL (NYSE: ICL) reported 2025 consolidated sales of $7,153 million, up 5% year-over-year, with adjusted EBITDA of $1,488 million and adjusted diluted EPS of $0.36. Q4 sales were $1,701 million (+6%), adjusted EBITDA $380 million (+10%).
The company took $239 million of unusual adjustments in Q4, including a $80 million provision tied to a Supreme Court ruling on Dead Sea water fees and ~$122 million of strategy-related charges. ICL closed the acquisition of Bartek Ingredients, reviewed non-core assets, discontinued LFP downstream projects, and set 2026 adjusted EBITDA guidance of $1.4–1.6 billion.
ICL (NYSE: ICL) will release fourth quarter 2025 results before the TASE open on Wednesday, February 18, 2026. A conference call with Elad Aharonson, president and CEO, and Aviram Lahav, CFO, will follow at 8:30 a.m. New York time.
Analyst dial-in numbers and a webcast for employees, media and the public are provided; a replay will be available online within approximately 24 hours.
ICL (NYSE: ICL) agreed to acquire Bartek Ingredients, a global leader in food‑grade malic and fumaric acid that generates about $65 million in annual revenue and serves customers in 40+ countries.
The transaction will close in two phases: an initial cash investment of approximately $90 million for ~50% of Bartek expected to close in Q1 2026, and a second‑phase purchase subject to business and integration milestones. Bartek is building a new production facility due in 2026 to expand capacity. The deal is subject to customary regulatory approvals.
ICL (NYSE: ICL) reported 3Q 2025 results: consolidated sales of $1.85B (up $100M YoY) and adjusted EBITDA of $398M (+4% YoY). Reported operating income was $230M and adjusted operating income $241M. Adjusted net income was $124M (vs. $136M) and adjusted diluted EPS was $0.10 (vs. $0.11). The company reiterated specialties-driven EBITDA guidance of $0.95B–$1.15B for 2025 and expects potash volumes of 4.3–4.5M mt.
Strategic moves: focus on two growth engines (specialty crop nutrition and specialty food solutions), discontinuation of downstream LFP cathode projects (St. Louis and Spain), and an MOU on the Dead Sea concession. Dividend of 4.80 cents per share declared, payable Dec 17, 2025.
ICL (NYSE: ICL) will release third quarter 2025 results before the TASE open on Wednesday, November 12, 2025. A conference call with Elad Aharonson, president and CEO, and Aviram Lahav, CFO, is scheduled for 8:30 a.m. New York time (1:30 p.m. London, 3:30 p.m. Tel Aviv) to discuss results, provide a business update and answer questions.
North America dial-in: (800) 549-8228; international dial-in: (289) 819-1520; conference ID: 10635. The call will be webcast via the ICL Group investor relations site and a replay will be available online within approximately 24 hours.
ICL (NYSE: ICL), a global specialty minerals company, announced that Anantha Desikan, Executive Vice President and Chief Innovation and Technology Officer, will participate in a fireside chat at the Jefferies Industrials Conference 2025. The presentation is scheduled for September 3, 2025, at 4:10 p.m. ET.
Investors can access the live webcast through ICL's investor relations website, with a replay available for a limited time after the event.
ICL (NYSE: ICL), a global specialty minerals company, reported its Q2 2025 financial results with sales of $1.8 billion, up $80 million year-over-year. The company achieved operating income of $181 million and adjusted EBITDA of $351 million.
Key performance metrics include net income of $93 million and adjusted diluted EPS of $0.09. The company's specialties-driven businesses showed growth, while Potash segment faced challenges. ICL maintained its specialties-driven EBITDA guidance of $0.95-1.15 billion for 2025, but revised Potash sales volume expectations to 4.3-4.5 million metric tons due to geopolitical unrest.
Notable developments include new Potash contracts with India (400,000 metric tons at $349/ton) and China (750,000 metric tons at $346/ton). The company declared a dividend of 4.26 cents per share, payable September 17, 2025.
ICL (NYSE: ICL), a global specialty minerals company, will release its second quarter 2025 financial results before the TASE market opens on Wednesday, August 6, 2025. The company will host a conference call at 8:30 AM New York time featuring CEO Elad Aharonson and CFO Aviram Lahav to discuss results and provide business updates.
Financial analysts can join via dedicated dial-in numbers, while other stakeholders can access the webcast through ICL's Investor Relations website. A replay will be available online within 24 hours after the event.
Evogene (NASDAQ: EVGN) has completed the previously announced sale of its ag-biologicals subsidiary Lavie Bio to ICL Group (NYSE: ICL). The transaction includes the transfer of Lavie Bio's proprietary Biology Driven Design (BDD) technology platform, microbial bank, development pipeline, commercial products, and core personnel. Additionally, Evogene has divested its MicroBoost AI Tech-Engine for Agriculture to ICL.
The deal excludes Lavie Bio's existing strategic partnerships and commercial agreements, which will continue to generate potential future revenues for Lavie Bio's shareholders. This strategic move aligns with Evogene's goal to unlock subsidiary value while strengthening ICL's position in the global ag-biologicals market.